Cargando…
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
Hemophagocytic Lymphohistiocytosis (HLH) is a rare syndrome characterized by ineffective T-cell and NK response. We report the clinical course of a patient with relapsed CLL who developed acute symptoms soon after starting ibrutinib. Hyperpyrexia, splenomegaly, hyperferritinemia, hypertriglyceridemi...
Autores principales: | Cavallari, Maurizio, Ciccone, Maria, Falzoni, Simonetta, Cavazzini, Francesco, Formigaro, Luca, Di Virgilio, Francesco, Rotola, Antonella, Rigolin, Gian Matteo, Cuneo, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288319/ https://www.ncbi.nlm.nih.gov/pubmed/28180067 http://dx.doi.org/10.1016/j.lrr.2017.01.002 |
Ejemplares similares
-
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
por: Sessa, Mariarosaria, et al.
Publicado: (2020) -
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death
por: Salaro, Erica, et al.
Publicado: (2016) -
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019) -
Relapsing Kikuchi-Fujimoto Disease With Hemophagocytic Lymphohistiocytosis
por: Valente, Tiago, et al.
Publicado: (2022) -
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)